+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepcidin - Pipeline Review, H1 2020

  • ID: 4911701
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 44 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Panorama Research Inc
  • MORE
Hepcidin - Pipeline Review, H1 2020

Summary

According to the recently published report 'Hepcidin - Pipeline Review, H1 2020'; Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) pipeline Target constitutes close to 6 molecules.

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.

The report 'Hepcidin - Pipeline Review, H1 2020' outlays comprehensive information on the Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Hematological Disorders, Genetic Disorders, Immunology and Oncology which include indications Acute Inflammation, Hemochromatosis, Anemia, Anemia in Chronic Kidney Disease (Renal Anemia), Iron Deficiency Anemia, Myelodysplastic Syndrome, Polycythemia Vera, Sickle Cell Disease and Thalassemia.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
  • The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Daiichi Sankyo Co Ltd
  • Panorama Research Inc
  • MORE
  • Introduction
  • Report Coverage
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Overview
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Companies Involved in Therapeutics Development
  • Daiichi Sankyo Co Ltd
  • Panorama Research Inc
  • Pieris Pharmaceuticals Inc
  • Protagonist Therapeutics Inc
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drug Profiles
  • DS-28120313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-42450411 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DS-79182026 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRS-080 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PTG-300 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Dormant Products
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Discontinued Products
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Pipeline by Panorama Research Inc, H1 2020
  • Pipeline by Pieris Pharmaceuticals Inc, H1 2020
  • Pipeline by Protagonist Therapeutics Inc, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Daiichi Sankyo Co Ltd
  • Panorama Research Inc
  • Pieris Pharmaceuticals Inc
  • Protagonist Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll